StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Repatha Outcomes Data Reinforces Regeneron (REGN) Praluent Model - BTIG
March 17, 2017 11:52 AM
BTIG analyst Dane Leone weighed in on Regeneron Pharma (NASDAQ: REGN), saying the Repatha Outcomes Data Reinforces our Model Forecast ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Medicines Co. (MDCO), Esperion Therapeutics (ESPR) Plunge Following Amgen's (AMGN) Repatha Data
March 17, 2017 9:04 AM
Amgen (AMGN), Peers on Watch Ahead of Repetha Data at ACC.17 (REGN) (ESPR) (MDCO)
March 17, 2017 6:59 AM
Oppenheimer Starts Regeneron Pharma (REGN) at Perform
March 17, 2017 1:04 AM
